Literature DB >> 24715305

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Jun Li1, Yunfeng Yao, Juehua Jing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24715305     DOI： 10.1007/s13277-014-1924-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  1 in total

1.  The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Authors:  Xuan Wang; Chun Huang; Man Li; Yanjun Gu; Yanfen Cui; Yan Li
Journal:  Tumour Biol       Date:  2014-02-26
  1 in total
  2 in total

Review 1.  Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Authors:  Mei Liu; Zhiyang Li; Jingjing Yang; Yanyun Jiang; Zhongsi Chen; Zeeshan Ali; Nongyue He; Zhifei Wang
Journal:  Cell Prolif       Date:  2016-06-16       Impact factor: 6.831

2.  Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.

Authors:  Jinxin Shi; Peng Gao; Yongxi Song; Xiaowan Chen; Yuan Li; Changwang Zhang; Hongchi Wang; Zhenning Wang
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.